Commercial · in active development; the public site shows how a program works
NextConsensus
Tracks when medical evidence moves ahead of guidelines.
AI product leader and hands-on builder · Chicago · Open to relocation
Doximity Dialer, which I originated as founding product lead. Doximity’s own figures, February 2026.
14 years as a product leader and hands-on builder, making products in clinical care, oncology and AI, after training in biomedical engineering and molecular-biology research. See where I’d fit →
The two products deal with one problem: records that go out of date while people still rely on them, like a guideline that no longer matches the evidence.
Commercial · in active development; the public site shows how a program works
Tracks when medical evidence moves ahead of guidelines.
Experimental · open source, with a live demo and a roadmap that says what is not built
Distinguishes the tools an agent can reach from the actions it is authorized to take.
I come in before there’s a roadmap, build an unproven idea far enough to see whether it holds, and then decide what to scale, what to cut, and who should own it.
I originated Doximity Dialer, led R&D at CancerCompass, and co-founded Andwise. Andwise showed in year one that physicians wanted it; I did not work out who would pay until year two, and by then every path that could fund growth made someone other than the physician the paying customer. I chose to wind down the company in 2024. Since then I have built NextConsensus, Ambit, and Refract, putting new AI capabilities into production alongside cross-functional teams.
Decided by approval
Physicians calling from a personal phone had to expose their number or hide it behind “Unknown Caller,” making patients less likely to answer. As founding product lead, I originated the identity layer that let the call come from their own phone while the patient saw the office number — so it got answered, and the cell stayed private.
Read case study →Decided by accountability
Four specialty-care programs launched on one shared architecture.
Read case study →Decided by who pays
1,200+ physician users, then a deliberate wind-down when the fundable paths changed who the product would serve.
Read case study →Revised